Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_assertion type Assertion NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_head.
- NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_provenance.
- NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_assertion evidence source_evidence_literature NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_provenance.
- NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_assertion SIO_000772 19357717 NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_provenance.
- NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_assertion wasDerivedFrom befree-20140225 NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_provenance.
- NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_assertion wasGeneratedBy ECO_0000203 NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_provenance.